Better apart: a la Abbott, Baxter split in two

Baxter International is splitting into two companies – one focused on biopharmaceuticals and the other on medical products. In much the same way and citing the same "compelling rationale" that Abbott did just over two years, chairman and CEO Robert Parkinson says the two businesses have unique growth prospects, investment requirements and risk profiles that would be best served separately (scripintelligence.com, 19 October 2011).

Baxter International is splitting into two companies – one focused on biopharmaceuticals and the other on medical products. In much the same way and citing the same "compelling rationale" that Abbott did just over two years, chairman and CEO Robert Parkinson says the two businesses have unique growth prospects, investment requirements and risk profiles that would be best served separately (scripintelligence.com, 19 October 2011).

The markets agreed, sending Baxter's share price up by 9% in pre-market trading on Nasdaq over the previous day's close.

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Dermatological

More from Therapeutic Category